Une vraie bousculade dans les starting-blocks augure très mal des chances de la gauche d’être présente au second tour de l’élection présidentielle 2022. Et maintenant, c’est Montebourg qui
Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants Data on the company s investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST
Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant.
Mi India launches the Mi TV 4A 40 Horizon Edition
June 01, 2021
The Mi TV 4A 40 Horizon Edition is priced at ₹23,999
Xiaomi’s Mi India has announced the launch of its new Mi TV 4A 40 Horizon Edition smart TV, expanding its Horizon Edition TV series.
The Mi TV 4A 40 Horizon Edition comes with a 40-inch horizon display with a 93.7 per cent screen to body ratio and 178-degree viewing angle. It features a bezel-less elegant design.
It also features Mi’s proprietary Vivid Picture Engine (VPE) technology.
The TV is powered with an enhanced version of PatchWall that allows users to explore a range of content from over 25 content partners such as Disney+ Hotstar, Prime Video, etc.
(0) Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy.
For people with chronic gout refractory to conventional therapies (uncontrolled gout), KRYSTEXXA offers a unique mechanism of action that converts urate into allantoin which can more easily and efficiently be excreted by the kidneys.
1 Similar to other biologic medicines, patients on KRYSTEXXA monotherapy can develop anti-drug antibodies that prevent them from completing a full course of therapy. Increasingly, immunomodulating therapies, such as methotrexate, have been employed to help reduce the development of anti-drug antibodie